FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab to treat moderate-to-severe plaque psoriasis. Merck, which since 2014 ... Read more